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Pulmonaryvein isolation with catheter ablation is an eﬀective treatment in patients with symptomatic atrial ﬁbrillationrefractory
or intolerant to antiarrhythmic medications. The cryoballoon catheter was recently approved for this procedure. In this paper,
the basics of cryothermal energy ablation are reviewed including its ability of creating homogenous lesion formation, minimal
destruction to surrounding vasculature, preserved tissue integrity, and lower risk of thrombus formation. Also summarized here
are the publications describing the clinical experience with the cryoballoon catheter ablation in both paroxysmal and persistent
atrial ﬁbrillation, its safety and eﬃcacy, and discussions on the technical aspect of the cryoballoon ablation procedure.
1.Introduction
Atrialﬁbrillation (AF)isthemost commonsustainedcardiac
rhythm disturbance, increasing in prevalence with age [1].
Pulmonary vein (PV) isolation with catheter ablation is one
of the primary treatments for symptomatic AF refractory
or intolerant to antiarrhythmic medications [1]. In some
cases, it may be even appropriate to perform AF ablation
as ﬁrst-line therapy, particularly in selected symptomatic
patients with heart failure and/or reduced left ventricular
ejection fraction [2]. The main goal in catheter ablation is
complete electrical isolation of the PVs, and therefore the
success of the procedure and the reduction of procedure-
related complications require careful identiﬁcation of the PV
ostia and application of ablation to the PV antra.
Currently radiofrequency (RF) energy is the most
commonly used energy source for ablation. Many studies
demonstrated the eﬃcacy of RF energy for the treatment
of AF. However, this form of energy is associated with
variouscomplicationsincludingthromboembolicevents,PV
stenosis, and atrio-esophageal ﬁstula [3]. Thus, new energy
sources have been investigated for the treatment of AF.
These include cryothermal energy, ultrasound, and laser [4].
Recent clinical and preclinical studies demonstrated that the
cryothermal energy application using a balloon catheter for
PV isolation is an eﬀective treatment for AF [5, 6].
The purpose of this paper is to review the current litera-
ture for better understanding of the utility of cryoablation
for the treatment of patients with AF. The literature was
searched in PubMed from 1950 to February 2011 with the
keywords “atrial ﬁbrillation,” “cryosurgery,” and “catheter
ablation” published in English. A total of 100 references
were found. All full-text articles and their references were
reviewed and included in this paper if they were relevant to
our presentation.
2.Effectsof CryothermalEnergyat
the CellularLevel
Cryothermal energy causes progressive necrosis in the
absence of signiﬁcant alteration of tissue structure at thaw.
The eﬀect of ablation on the cellular ultrastructure has been
evaluated in studies using a cryoprobe cooled to −60◦Cw i t h
expanding nitrous oxide [7] .I c ec r y s t a l sw e r eo b s e r v e dt o
form inside the cells during ablation, with a resulting cell
damage that is osmotic rather than mechanical [7]. Micro-
circulatorychangeshavealsobeendescribedleading totissue
necrosis. Acute changes in subcellular organelle structure
and mitochondrial destruction occur in 1 minute at −70◦C.
The mitochondria appear enlarged, with decreased matrix
density and disrupted cristae. Striking depletion of glycogen
stores takes place within 1 hour of thaw. Subsequent changes
up to 10 hours after thaw are most notable for progressive
mitochondrial damage. Then, the hemorrhagic and inﬂam-
matory phase starts and results in ﬁbrosis. The cryothermal2 Cardiology Research and Practice
energy lesion formation can be divided in three sequential
stages which are the freeze/thaw phase, the hemorrhagic-
inﬂammatory phase, and the replacement ﬁbrosis phase.
The resulting lesions are minimally thrombogenic, have
sharp well-demarcated margins, and exhibit minimal tissue
disruptionandpreservedbasicunderlyingtissue architecture
[8, 9]. Thus the histopathologic changes of cryoablation are
likely to be associated with low arrhythmogenic potential.
3.ClinicalApplicationofCryoablation
Cryothermal energy has been used in treatment of cardiac
arrhythmias for the past 3 decades, especially in supraven-
tricular arrhythmias. Cryoablation was performed as early
as 1977 to the atrioventricular (AV) conduction system
[10]. Harrison et al. studied cryoablation using a hand-
held nitrous oxide-cooled cryogenic probe in 20 dogs and
subsequently in three patients with drug-resistant, life-
threatening supraventricular tachycardias [10]. In the same
year accessory pathway elimination by cryoablation was
demonstrated by Gallagher et al. [11]. Since then, numerous
experimental and clinical studies have evaluated the eﬃcacy
and safety of cryoablation [4, 5, 9, 12–14].
A multicenter clinical trial in patients with AV nodal
reentry tachycardia (103 patients), AV reentrant tachy-
cardia (51 patients), and AF (12 patients) demonstrated
that cryoablation is a safe and eﬀective strategy for the
treatment of supraventricular arrhythmias [12]. Catheter-
based cryoablation was found to be a safe alternative to RF
ablation for slow pathway modiﬁcation, accessory pathway
termination, and AV junction ablation. Acute procedural
success was achieved in 83% of the overall group, and
long-term success after 6 months was 91%. Cryomapping
(cooling the catheter tip to −30◦C) successfully identiﬁed
ablation targets in the majority of the patients, and the
electrophysiologic eﬀects of cryomapping were reversible
within minutes in 94% of the attempts.
Also, a prospective, randomized trial in patients with
recurrent narrow QRS-complex tachycardia suggestive of
AV nodal reentry tachycardia compared cryoablation with
RF ablation and showed a procedural success rate of 91%
in the RF group and 93% in the cryoablation group
[13]. The median number of cryothermal applications was
signiﬁcantly lower than the number of RF applications.
Both ﬂuoroscopy and procedural times were comparable.
No cryoenergy-related complications were observed, and
no permanent AV conduction block occurred. Long-term
clinical success was comparable in both groups.
Currently cryoablation is used to treat various forms of
ventricular and supraventricular arrhythmias including AV
nodal reentry tachycardia, AV reentrant tachycardia, atrial
ﬂutter, and focal atrial tachycardia [12–18]. Compared to
RF ablation, cryoablation has been associated with lack of
pain during energy delivery, homogenous lesion formation,
less destruction to surrounding vasculature, preserved tissue
integrity, and lower risk of thrombus formation [5–9, 12–
14]. Lesion reversibility is another advantage of cryoablation
over RF energy and is useful for ablation of accessory
pathways in proximity to the conduction system [12–
15]. Moreover, cryoablation can be applied within venous
structures, like the coronary sinus and the middle cardiac
vein with less risk of thrombosis compared to RF ablation
[14, 19]. It has been shown that cryoablation in the coronary
sinus within 2mm of the left circumﬂex artery produces
myocardial lesions similar to RF ablation with lower risk of
coronary artery stenosis [19].
The absence of endothelial disruption with cryoablation
r e s u l t si nl e s st h r o m b o g e n i c i tya n dm a yo ﬀeran opportunity
for improved safety during ablations in the left side of the
heart [5–9]. This may be important when large areas of the
endocardium are ablated such as in AF ablation procedures.
All these characteristics of cryoenergy, in addition to the
ability to use it with a balloon, make it an attractive source
of energy for PV isolation.
4.Balloon-Based AblationCatheter
Point-to-point ablation using a focal catheter for PV iso-
lation is associated with technical diﬃculties and requires
experienced operators with high level of skills. Pulmonary
vein isolation using a focal cryocatheter has been studied
and was found to be associated with long procedure times
[20]. The cryoballoon catheter was designed with the aim of
facilitating PV isolation [4–6, 21].
5.Cryoballoon forPulmonaryVeinIsolation
5.1.AblationTechnique. Currentlyonlyoneballoondesignis
available for clinical use (Medtronic Inc, Minnesota, Minn).
Thissystemincludesanover-the-wireballooncatheterwhich
is cooled using nitrous oxide (N2O) [4–6, 22–27]. The
balloon shaft size is 10.5F and has a deﬂection mechanism.
It is introduced into the left atrium using a 14 Fr steerable
sheath. The shaft has a central lumen that can accommodate
a wire for support and also used for contrast and saline
injection.
The wire is used to engage the vein ﬁrst. The balloon
is inﬂated outside the vein and advanced over the wire to
occlude the vein (Figure 1). Obtaining a complete occlusion
is crucial for successful isolation. An incomplete occlusion
will lead to ﬂow around the balloon and prevents the
temperature from reaching low enough levels necessary
for adequate ablation. A complete occlusion is typically
conﬁrmed by injecting contrast in the lumen at the balloon
tip. Once occlusion is conﬁrmed, the contrast is ﬂushed
using saline and freezing is started. If successful, a dip in the
temperature curve is observed indicating a better occlusion.
Lesions are usually 240–300sec long and PV isolation is
usually achieved with one lesion in most patients [22–24].
Most operators apply one additional lesion after isolation.
Currently, two sizes of the cryoballoon catheter are
available, 28mm and 23mm diameter. It is advisable to
use a 28mm balloon regardless of the size of the vein
in order to reduce the risk of complications such as PV
stenosis and phrenic nerve injury. A quadripolar catheter is
usually positioned in the superior vena cava for continuousCardiology Research and Practice 3
Figure 1: Cryoballoon catheter placement for pulmonary vein iso-
lation with ﬂuoroscopic A. Fluoroscopic appearance (30◦ left ante-
rior oblique view) of the cryoballoon inﬂated in a left superior
pulmonary vein. The guidewire was advanced in a pulmonary vein
branch, and the occlusion is conﬁrmed by the absence of ﬂow
during contrastinjection in the vein. The circular mappingcatheter
is placed at the ostium of the right superior pulmonary vein.
A multipolar catheter in the coronary sinus and an intracardiac
echocardiography catheter in the mid-right atrium are visible.
phrenic nerve stimulation during cryoablation of right PVs.
Intracardiac echocardiogram and color Doppler can be used
toconﬁrmocclusionandthesiteofgaps ifpresent (Figure2).
Recently, the use of transesophageal echocardiography with
colorDopplerwas described allowing real-time visualization
of the cryoballoon during ablation [28].
After ablation, PV isolation is assessed using a circular
mapping catheter inserted in the left atrium via a separate
transseptal puncture [22, 25, 29]. A small caliber circular
mapping that can be advanced in the central lumen instead
of the wire can also be used to conﬁrm isolation.
In some patients technical challenges can be encountered
leading to the inability to obtain a complete occlusion. Two
maneuvers can be helpful if complete occlusion cannot be
achieved by advancing the balloon. The ﬁrst involves trying
to engage a diﬀerent branch with the wire. This can provide
a better alignment of the catheter shaft with the axis of the
PV. The second maneuveris the “pull-down” technique [24].
This can be useful when a gap is present at the inferior
border of the vein and cannot be closed despite advancing
the balloon. With this technique, freezing is started despite
the presence of the gap. At about 60–90sec into the freeze,
the balloon and the sheath are both pulled down gently in
order to close the gap at the inferior portion of the vein. This
should be done very carefully because of the risk of severe
vascular damage if excessive force is applied. If occlusion
and isolation cannot be obtained despite these maneuvers,
a standard point-by-point ablation catheter can be used for
completion.
The sites of PV reconnection have been analyzed in some
studies [24, 29–31] .T h ei n f e r i o rb o r d e ro ft h ev e i n sa sw e l l
Figure 2: An intracardiac echocardiographic image demonstrates
total occlusion of left superior pulmonary vein by cryoballon
catheter.
as the ridge between the left atrial appendage and the left PV
wasfoundtobethesiteswheremostreconnectionsoccurred.
This is likely to be the result of sharp catheter angulation
with loss of central cryoballoon alignment with the axis of
the PVs.
5.2. Clinical Results: Eﬃcacy of the Procedure. To date over
10,000 PV procedures have been performed worldwide.
There have been many publications describing the clinical
experience with the cryoballoon in both paroxysmal and
persistent AF [22–41].
An early report by Van Belle and colleagues described
57 consecutive patients with paroxysmal AF who underwent
cryoballoon ablation [22]. Eighty-four percent of the tar-
geted PVs were successfully isolated using the cryoballoon
and the rest required a standard cryocatheter to achieve
isolation. A daily monitoring of rhythm demonstrated a
signiﬁcant reduction in AF burden. Klein et al. reported
the result of cryoballoon ablation in 21 patients with
symptomatic paroxysmal AF in 2008 [26]. A total of 95%
of PVs were isolated, and 86% of the patients remained free
of AF after 6 months based on periodic holter monitoring.
Subsequently, Neumann et al. evaluated the eﬃcacy of
cryoballoon ablation in 293 patients with paroxysmal and
53 patients with persistent AF [23]. Ninety-seven percent
of the PVs were isolated with either cryoballoon alone or
in combination with a standard cryocatheter. Maintenance
of sinus rhythm was reported in 74% and 42% of the
patients with paroxysmal and persistent AF, respectively. In
a recent study by Ahmed et al. [24], the permanence of PV
isolation after cryoballoon ablation was tested in 12 patients
with paroxysmal AF. Eighty-eight percent of PVs remained
isolated at 8–12 weeks after the initial procedure.
The most comprehensive result regarding the eﬃcacy
and safety of the cryoballoon catheter ablation for the4 Cardiology Research and Practice
treatment of AF was obtained from the STOP-AF trial
[32, 33]. This trial randomized patients with paroxysmal
drug-refractory AF in a 2:1 fashion to either PV isolation
with cryoballoon ablation or antiarrhythmic drug therapy.
Balloon-only isolation of PVs was achieved in 90.8%, and
theoverallproceduralsuccess(≥3PVs isolated)wasachieved
in 98.2% of the patients. Nineteen percent of the patients
needed a repeat cryoablation procedure within the 90-day
blanking period. The success rate at 12-month followup was
69.9%.
The use of cryoballoon for PV isolation in patients
with persistent AF has been associated with high rates of
arrhythmia recurrence [23, 34, 35]. This is not surprising
knowing that the left atrial substrate and not only the PVs
play a role in AF maintenance in this subgroup of patients.
A study from our group investigated the combined use of
cryoballoon PV isolation and conventional RF ablation of
areas of complex fractionated electrograms in 22 patients
with persistent AF [27]. After a single procedure, 86% of
patients were AF-free at 6-month followup.
In this study the followup was performed in most
patients using implantable loop monitors allowing auto-
matic detection of asymptomatic AF. In addition to AF-
free survival, AF burden reduction was also analyzed in
some studies. Van Belle et al. studied 144 patients with
symptomatic AF refractory to antiarrhythmic drugs who
underwent cryoballoon PV isolation [36]. Followup was
performedusingdailytranstelephonicECGmonitoring,24h
Holter-ECG, and an arrhythmia-focused questionnaire to
document AF. After ablation, AF burden was reduced from
26% to 9%.
5.3. Complications of Cryoballoon Catheter Ablation. Phrenic
nerve palsies (PNP), PV stenosis, and other complications
have been reported with cryoballoon PV isolation [22–41].
In the STOP AF study, PNP was reported in 29 out of 259
procedures (11.2%) [32, 33]. Of these, only four (13.8%)
patients had persistent PNP at 12 months. PNP can occur
with isolation of the right superior and less commonly the
right inferior PV.
Another important procedural complication with the
cryoballoon is PV stenosis. Although earlier studies showed
nosigniﬁcant incidenceofPVstenosisfollowing cryoballoon
ablation, STOP-AF trial demonstrated 3.1% risk of PV
stenosis in its study population [32, 33]. This complication
is likely associated with ablation of the tubular portion of
the vein. As a result, it is believed that the use of the 28mm
balloon can reduce this complication because this larger
balloon is less likely to be positioned inside the vein during
ablation [25]. For the same reason, it is believed that the use
of the larger balloon will carry a lower risk of PNP.
There are no reports of atrioesophageal ﬁstula associated
with the use of the cryoballoon. The eﬀect of cryoballoon
PV isolation on the esophagus has been studied [37].
Luminal esophageal temperature was signiﬁcantly decreased
(>1 degrees C) in 62 of 67 (93%) patients, and reversible
esophageal injuries were seen in 17% of patients. However,
no atrial-esophageal ﬁstula was documented and the follow-
up endoscopy conﬁrmed healing of all ulcers.
Other procedure-related complications with the use of
the cryoballoon are similar to RF ablations including stroke,
pericardial eﬀusion or tamponade, femoral vein access
complications, and cerebral embolism [22–41].
5.4. Comparison with Conventional Radiofrequency Catheter
Ablation. Both conventional focal RF ablation and cryoab-
lation are used for PV isolation and both are shown to
be eﬀective [1–3, 22–44]. Recent studies compared clinical
outcome of cryoballoon ablation for PV isolation with RF
ablation in regards to the safety and the eﬃcacy of the
procedure [30, 35, 42].
Linhart et al. demonstrated in a case-control study of 40
patients with paroxysmal atrial ﬁbrillation that cryoballoon
ablation has similar success rate to RF ablation in addition
to similar procedure and ﬂuoroscopy times [42]. Kojodjojo
et al. studied the eﬃcacy of a strategy using a large
cryoballoon to perform antral PV isolation in 124 patients
with paroxysmal and persistent AF [35]a n dc o m p a r e di t
with RF ablation. At one-year followup, 77% of paroxysmal
and 48% of persistent AF patients remained free from AF
after a single procedure. In the RF group 72% of the patients
with paroxysmal remained free of AF. The procedural and
ﬂuoroscopic times with cryoablation were shorter than RF
ablation. A recent study from K¨ uhne at al. conﬁrmed the
shorter procedure duration with cryoablation compared to
RF (166 ± 32 versus 197 ± 52 minutes) [30]. In this study,
a total of 55 patients with paroxysmal AF were studied: 25
patients underwent PVI using a 28-mm cryoballoon and 25
patients using an open-irrigation RF catheter. The number
of procedures was not diﬀerent in the 2 groups (1.2 ± 0.4 in
cryoablation versus 1.3 ± 0.6 in RF ablation) with a success
rate at one-year followup of 88% in the cryoballoon group
and 92% in the RF group. Another study, the Freeze AF trial,
is being planned to compare cryoballoon catheter ablation
with open-irrigation RF ablation in a randomized clinical
study including 244 patients with paroxysmal AF [43].
6.Conclusions
Cryoballoon catheter ablation is a safe and eﬀective tech-
nique for PV isolation to treat paroxysmal AF. Overall
success rate in persistent AF is lower. Potential procedural
complications related to cryoballoon ablation include PNP
and PV stenosis as well as rare neurological complications.
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